RHAPSODY: a pivotal phase 3 trial to assess efficacy and safety of rilonacept, an interleukin 1 alpha and beta blocker, in patients with recurrent pericarditis
2 September 2019 (08:30 - 12:30)
Organised by:
Abstract
Slides
About the speaker
University Hospital Santa Maria della Misericordia, Udine (Italy)
11 More presentations in this session
Access the full session
The Event
ESC Congress 2019
2 September 2019
08:30 CET
You may be interested in
Congress Session
Congress Session
